Imvax Glioblastoma Data Backs Move Toward Phase 3 Trial
PHILADELPHIA, PA — Imvax Inc. is preparing a roughly 375-patient Phase 3 trial of its experimental glioblastoma therapy IGV-001 after a prespecified Phase 2b subgroup analysis showed longer median survival …
Imvax Glioblastoma Data Backs Move Toward Phase 3 Trial Read More